文献速递泌尿男性生殖肿瘤

MAGNITUDE 3期研究中基线特征失衡的调整证实尼拉帕利联合醋酸阿比特龙加泼尼松对转移性前列腺癌患者的临床获益

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
PubMed 文献 · Eur J Cancer · 2024-06-17

基于MAGNITUDE研究(NCT03748641)中225例BRCA1/2突变转移性去势抵抗性前列腺癌患者,采用逆概率治疗加权(IPTW)调整基线协变量失衡后评估至事件时间结局。尼拉帕利+醋酸阿比特龙+泼尼松(+AAP)较安慰剂+AAP的调整后中位总生存为34.1个月 vs 27.4个月(HR 0.65;95%CI 0.46,0.93;p=0.017),未调整中位总生存为30.4个月 vs 28.6个月(HR 0.79;95%CI 0.55,1.12;p=0.183)。

要点

  • IPTW调整后尼拉帕利+AAP较安慰剂+AAP中位OS为34.1个月 vs 27.4个月(HR 0.65;95%CI 0.46,0.93;p=0.017)。
  • 未调整中位OS为30.4个月 vs 28.6个月(HR 0.79;95%CI 0.55,1.12;p=0.183)。
  • 其他至事件时间终点也观察到类似改善。

核心结论

  • IPTW调整提供了尼拉帕利+AAP相较安慰剂+AAP在BRCA1/2突变mCRPC患者中临床获益的更精确估计,结果与预先设定的多变量分析一致,并进一步证明调整基线失衡的价值,尤其是在较小研究中。

研究设计与样本

  • 对MAGNITUDE研究(NCT03748641)中BRCA1/2突变mCRPC患者(N=225)的至事件时间结局进行逆概率治疗加权(IPTW)分析,患者接受尼拉帕利+AAP或安慰剂+AAP。

主要发现

  • 未调整中位OS为尼拉帕利+AAP组30.4个月 vs 安慰剂+AAP组28.6个月(HR 0.79;95%CI 0.55,1.12;p=0.183)。
  • IPTW后中位OS为尼拉帕利+AAP组34.1个月 vs 安慰剂+AAP组27.4个月(HR 0.65;95%CI 0.46,0.93;p=0.017)。
  • 其他至事件时间终点也观察到类似改善。

关键数值与推荐

  • 评估终点包括总生存、影像学无进展生存、至症状性进展时间、至开始细胞毒性化疗时间和至前列腺特异性抗原进展时间。
  • 为每个终点生成加权Kaplan-Meier曲线,并从加权Cox模型获得调整后风险比(HR)。

局限性

  • 原文报告了组间预后变量存在失衡,影响对尼拉帕利+AAP临床获益和成本效果的估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MAGNITUDE (NCT03748641) demonstrated favourable outcomes with niraparib plus abiraterone acetate plus prednisone (+AAP) versus placebo+AAP in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC). Imbalances in prognostic variables were reported between arms, which impacts estimation of both the clinical benefit and cost‑effectiveness of niraparib+AAP for healthcare systems. A pre-specified multivariable analysis (MVA) demonstrated improved overall survival (OS) with niraparib+AAP. Here, we used an inverse probability of treatment weighting (IPTW) model to adjust for covariate imbalances and assess time-to-event outcomes. METHODS: IPTW analysis of time-to-event outcomes was conducted using data from patients with BRCA1/2-altered mCRPC (N = 225) in MAGNITUDE. Patients received niraparib+AAP or placebo+AAP. OS, radiographic progression-free survival, time to symptomatic progression, time to initiation of cytotoxic chemotherapy and time to prostate-specific antigen progression were assessed. Weighted Kaplan-Meier curves were generated for each endpoint, and adjusted hazard ratios (HR) were obtained from a weighted Cox model. RESULTS: Improvements in survival outcomes were estimated for niraparib+AAP versus placebo+AAP: unadjusted median OS was 30.4 months versus 28.6 months, respectively (HR: 0.79; 95 % confidence interval [CI]: 0.55, 1.12; p = 0.183). Following IPTW, median OS increased to 34.1 months with niraparib+AAP versus a decrease to 27.4 with placebo (HR: 0.65; 95 % CI: 0.46, 0.93; p = 0.017). Similar improvements were observed for other time-to-event endpoints. CONCLUSIONS: IPTW adjustment provided a more precise estimate of the clinical benefit of niraparib+AAP versus placebo+AAP in patients with BRCA1/2-altered mCRPC. Results were consistent with the pre-specified MVA, and further demonstrated the value of adjusting for baseline imbalances, particularly in smaller studies. TRIAL REGISTRATION: NCT03748641 (MAGNITUDE).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roubaud G, Attard G, Boegemann M, et al. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. Eur J Cancer. 2024. PMID: 39111209. doi:10.1016/j.ejca.2024.114183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。